ERBB2 and lung cancer: Whereas non–small cell lung cancer represented the highest proportion of ERBB2-mutated (i.e., single-nucleotide variants and short insertions/deletions) cancers (19.0%), breast, colorectal, bladder, and gastroesophageal cancers combined accounted for 50.4% of ERBB2-mutated tumors.